Junshi Biosciences and Coherus Present Results of Phase 3 Study of Toripalimab in First Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma at 2022 AACR Annual Meeting
– Toripalimab plus chemotherapy provided superior progression free survival, overall survival, overall response rate and…
Indonesia Urges Greater Transparency in Cross-Border Copyright Royalty Governance Before 35 Countries
SaunaKits.com Opens Its Upstate South Carolina Showroom, Bringing Hands-On Sauna Shopping to the Southeast
Encore Construction Shares Guidance to Help Homeowners Avoid Costly Water Damage Insurance Claim Mistakes